Nicotine Patch + Placebo Patch + SLS Comparator Patch

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

May 1, 2005 โ†’ Jun 1, 2005

About Nicotine Patch + Placebo Patch + SLS Comparator Patch

Nicotine Patch + Placebo Patch + SLS Comparator Patch is a phase 1 stage product being developed by Johnson & Johnson for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00967174. Target conditions include Smoking Cessation.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00967174Phase 1Completed

Competing Products

20 competing products in Smoking Cessation

See all competitors
ProductCompanyStageHype Score
Brenipatide + PlaceboEli LillyPhase 2
52
Nicotine + Nicotine + NicotineJohnson & JohnsonPhase 2
52
Nicotine replacement therapy + Nicotine replacement therapyJohnson & JohnsonPhase 2
52
Nicotine Patch + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine + PlaceboJohnson & JohnsonPre-clinical
23
Nicotine Patch + Nicotine Patch Comparator + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine Patch + Placebo Patch + No Patch ControlJohnson & JohnsonPhase 1
33
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3
77
Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved
85
AZD4041 + PlaceboAstraZenecaPhase 1
33
taranabantMerckPhase 2
52
Nicotine replacement therapyNovartisPre-clinical
23
AFQ065NovartisPhase 1
33
Liraglutide + PlaceboNovo NordiskPhase 2
51
VareniclinePfizerPhase 2
51
placebo + Varenicline TartaratePfizerPhase 3
76
varenicline + placeboPfizerApproved
84
varenicline (CP-526,555)PfizerPhase 3
76
placebo + vareniclinePfizerApproved
84
Varenicline + BupropionPfizerPhase 3
76